WP
PHAT icon

Woodline Partners’s Phathom Pharmaceuticals PHAT Stock Holding History

Woodline Partners’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.1M Buy
369,052
+181,761
+97% +$2.3M 0.02% 695
2025
Q4 		$3.11M Hold
187,291
– – 0.01% 713
2025
Q3 		$2.2M Hold
187,291
– – 0.01% 718
2025
Q2 		$1.8M Sell
187,291
-564,401
-75% -$3.12M 0.01% 738
2025
Q1 		$4.71M Sell
751,692
-250,000
-25% -$1.52M 0.03% 523
2024
Q4 		$8.13M Sell
1,001,692
-1,571,720
-61% -$19.5M 0.06% 393
2024
Q3 		$46.5M Buy
2,573,412
+1,787,422
+227% +$25M 0.39% 68
2024
Q2 		$8.1M Buy
785,990
+219,551
+39% +$2.26M 0.08% 277
2024
Q1 		$6.02M Sell
566,439
-529,682
-48% -$4.5M 0.06% 337
2023
Q4 		$10M Buy
1,096,121
+356,100
+48% +$3.07M 0.11% 227
2023
Q3 		$7.67M Buy
740,021
+66,333
+10% +$910K 0.09% 250
2023
Q2 		$9.65M Buy
+673,688
New +$7.77M 0.11% 212
2021
Q4 		– Sell
-29,903
Closed -$960K – 765
2021
Q3 		$960K Buy
+29,903
New +$994K 0.02% 520
2021
Q2 		– Sell
-41,678
Closed -$1.56M – 622
2021
Q1 		$1.56M Buy
+41,678
New +$1.74M 0.03% 316

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Woodline Partners's PHAT Position: Q1 2026 in Review

Woodline Partners increased its Phathom Pharmaceuticals (PHAT) stake by 97% in Q1 2026, buying an estimated $2.3M and bringing the position to 369,052 shares worth $4.1M. The position accounts for 0.02% of the portfolio, ranked #695.

Woodline Partners first reported a position in PHAT in Q1 2021 and has held it in 14 quarters since. The position peaked at $46.5M in Q3 2024. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Woodline Partners held 369,052 shares of Phathom Pharmaceuticals worth $4.1M as of Q1 2026.
  • Woodline Partners bought 181,761 Phathom Pharmaceuticals shares in Q1 2026, an estimated $2.3M.
  • Phathom Pharmaceuticals made up 0.02% of Woodline Partners's portfolio in Q1 2026, its #695 holding.
  • Woodline Partners first reported a position in Phathom Pharmaceuticals in Q1 2021 and has held it in 14 quarters since.
  • Woodline Partners's Phathom Pharmaceuticals position peaked at $46.5M in Q3 2024.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.